Outcomes after the surgery are improving, but researchers caution that it remains risky.

Spurred by her grandfather’s MI to pursue a career in medicine, this fellow finds inspiration in outcomes research.

Doctors might feel out of their element making the videos, but patients respond to the short, informative reels.

Data from implantable monitors show a low AF burden with time, leading some to question the need for oral anticoagulation.

The findings sparked a debate about the merits of RCTs vs other study designs—one surgeon urged others to “read a textbook.”

The drug met primary safety and efficacy outcomes, with full results to be presented at the AHA Scientific Sessions.

Among the changes are a lower TAVI age cutoff and greater emphasis on patient education and coronary CTA.

The document, last updated in 2017, promotes use of the PREVENT calculator as well as more flexible BP goals.

The decade-long, single-healthcare-system study gives insights into how physicians are using CAC tests and in which patients.

The serial imaging substudy shows that intensive therapy might change plaque morphology positively, researchers say.

From patient satisfaction to making family and mentors proud, fellows tell TCTMD they feel fulfilled in a variety of ways.

A special session at SCCT was dedicated to the history of the field, but also explored future directions and unanswered questions.

The “hypothesis-generating” results show that the technology might improve use of preventive therapies, especially in women.

The technology, which led to a shift in strategy more than half of the time, could save $719 per symptomatic patient over 10 years.

Scanning identified significant CAD in this high-risk population, even among those with zero CAC.

The study isn’t intended to sway clinical decision-making, but to make doctors aware of the impact of their choices.

The study isn’t intended to sway clinical decision-making, but to make doctors aware of the impact of their choices.

The study led to questions about whether patients would be best served by being treated at high-volume centers of excellence.

The procedures are not mutually exclusive, however, and should be considered on a patient-by-patient basis, a researcher says.

Azeem Latib and Jose Calle Gordo discuss "me too" vs disruptive approaches.

Dominick Angiolillo sums up all the data on this key clinical question.

With new CVD treatments arriving each year, “there’s no reason why outcomes should be getting worse,” says Jason Wasfy.

Davide Capodanno reflects on how he is able to serve the cardiology community through his role as the editor-in-chief at EuroIntervention.

In the ILIAS ANOCA trial, using CFT to guide treatment according to ANOCA endotype led to larger QoL gains over 6 months.